SCHEMBL2855642

SCHEMBL2855642

O=C(c1ccc2c(c1)c(-c1cccc(F)c1)nn2CO)c1cccs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.41
PTGER1 P34995 2/20 0.41
CNR1 P21554 1/20 0.38
GRM5 P41594 1/20 0.37
HPGD P15428 3/20 0.36
HTT P42858 2/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CDK2 P24941 1/20 0.35
HPGDS O60760 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861588 0.89 MAPT (0.39) CNR2PTGER1CNR1GRM5HPGD
SCHEMBL2862067 0.76 TTK (0.49) MEN1KMT2AMAPTJAK3
SCHEMBL2864808 0.70 MAPT (0.46) PTGER1GRM5HPGDHTTMEN1
SCHEMBL121336 0.67 PTGER1 (0.47) PTGER1HPGD
SCHEMBL2862660 0.65 PTGER1 (0.36) CNR2PTGER1HPGDHTTKMT2A
SCHEMBL31632883 0.64 CSNK2A2 (0.47) PTGER1HPGDHTTKMT2ASMN1; SMN2
SCHEMBL2857840 0.64 MAPT (0.41) PTGER1HPGDHTTMEN1KMT2A
SCHEMBL2074541 0.64 HPGDS (0.69) HPGDHTTMEN1KMT2AMAPT
SCHEMBL2863245 0.63 PTGER1 (0.43) PTGER1MAPTSMN1; SMN2
SCHEMBL30940072 0.63 HPGDS (0.58) CNR2CNR1HPGDHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CNR2 167/4885PTGER1 3143/4885CNR1 105/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 CNR2 277/4885PTGER1 4240/4885CNR1 132/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CNR2 167/4885PTGER1 3143/4885CNR1 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.